Pharmaceuticals Market Research Reports & Industry Analysis

Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.

The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.

The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.

Found 15614 publications
Pharmaceutical Preps. for Human use, against Parasitic & Infective diseases World Report US$ 4,250.00

PHARMACEUTICAL PREPS. FOR HUMAN USE, AGAINST PARASITIC & INFECTIVE DISEASES WORLD REPORT The Pharmaceutical Preps. for Human use, against Parasitic & Infective diseases World Report gives Market Consumption ...

Mar, 2015 2074 pages
Pharmaceutical Preparations, Human Use, Central Nervous System & Sense Organs World Report US$ 4,250.00

PHARMACEUTICAL PREPARATIONS, HUMAN USE, CENTRAL NERVOUS SYSTEM & SENSE ORGANS WORLD REPORT The Pharmaceutical Preparations, Human Use, Central Nervous System & Sense Organs World Report gives Market Consumption/ ...

Mar, 2015 2010 pages
Pharmaceutical Preparations for Veterinary Use World Report US$ 4,250.00

PHARMACEUTICAL PREPARATIONS FOR VETERINARY USE WORLD REPORT The Pharmaceutical Preparations for Veterinary Use World Report gives Market Consumption/Products/Services for over ...

Mar, 2015 2017 pages
Pharmaceutical Preparations for Human Use, Hormones & Synthetic Substitutes World Report US$ 4,250.00

PHARMACEUTICAL PREPARATIONS FOR HUMAN USE, HORMONES & SYNTHETIC SUBSTITUTES WORLD REPORT The Pharmaceutical Preparations for Human Use, Hormones & Synthetic Substitutes World Report gives Market Consumption/Products/ ...

Mar, 2015 2063 pages
Pharmaceutical Preparations for Human use, acting on the Skin World Report US$ 4,250.00

PHARMACEUTICAL PREPARATIONS FOR HUMAN USE, ACTING ON THE SKIN WORLD REPORT The Pharmaceutical Preparations for Human use, acting on the Skin World Report gives Market Consumption/Products/ ...

Mar, 2015 2174 pages
Pharmaceutical Preparations for Human Use Acting on the Respiratory System World Report US$ 4,250.00

PHARMACEUTICAL PREPARATIONS FOR HUMAN USE ACTING ON THE RESPIRATORY SYSTEM WORLD REPORT The Pharmaceutical Preparations for Human Use Acting on the Respiratory System World Report gives Market Consumption ...

Mar, 2015 2084 pages
Pharmaceutical Preparations for Human Use Acting on the Digestive System World Report US$ 4,250.00

PHARMACEUTICAL PREPARATIONS FOR HUMAN USE ACTING ON THE DIGESTIVE SYSTEM WORLD REPORT The Pharmaceutical Preparations for Human Use Acting on the Digestive System World Report gives Market Consumption ...

Mar, 2015 2087 pages
Pharmaceutical Preparations for Human Use Acting on the Cardiovascular System World Report US$ 4,250.00

PHARMACEUTICAL PREPARATIONS FOR HUMAN USE ACTING ON THE CARDIOVASCULAR SYSTEM WORLD REPORT The Pharmaceutical Preparations for Human Use Acting on the Cardiovascular System World Report gives Market Consumption ...

Mar, 2015 2167 pages
Drugs World Report US$ 4,250.00

DRUGS WORLD REPORT The Drugs World Report gives Market Consumption/Products/Services for over 200 ... Parameters, Marketing Costs, Markets, Decision Makers, Performance, Product Launch. WORLD & NATIONAL REPORT MARKET DATABASE & SPREADSHEETS. FINANCIAL SPREADSHEETS & DATABASES. INDUSTRY ...

Mar, 2015 2022 pages
Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015 US$ 3,500.00

... products and Asia Pacific with 18 ADCs in development. Scope A snapshot of the global Antibody-Drug Conjugate market scenario, market trends & drivers, manacles of Antibody-Drug Conjugate. A review of the marketed Antibody-Drug Conjugate products and marketing status Coverage of global antibody-drug conjugate ...

Mar, 2015 342 pages
Longevity Biotech, Inc - Product Pipeline Review - 2015 US$ 1,500.00

... pipeline projects Latest company statement Latest news and deals relating to the Longevity Biotech, Inc’s pipeline products Reasons to buy Evaluate Longevity Biotech, Inc ...

Feb, 2015 29 pages
Trends and Innovations in Drug Pricing US$ 595.00

FirstWord’s Trends and Innovations in Drug Pricing report dissects international trends and examines how long-standing dynamics in competitive pricing and ... research and expert interviews, Trends and Innovations in Drug Pricing is an open window to the future of drug pricing. Worldwide, the trend towards payers determining price has ...

Jan, 2015
Zanamivir - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Zanamivir Indications: Treatment or prophylaxis of infections due to Influenza A or B viruses Innovator:Glaxosmithkline (Relenza) Country ...

Mar, 2015
Vorapaxar - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Vorapaxar Indications: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease Innovator:Merck (Zontivity) Country ...

Mar, 2015
Voglibose - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Voglibose Indications: Lowering post-prandial blood glucose levels in people with diabetes mellitus Innovator:Mascot Health (Voglib) Country ...

Mar, 2015
Vildagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Vildagliptin Indications: Treatment of type 2 diabetes mellitus, optionally in combination with Metformin, a sulphonylurea, a thiazolidinedione or Insulin Innovator:Novartis (Galvus, Jalra, Icandra, Xiliarx, Zomarist, Eucreas, Sobrea, Galvumet) Country ...

Mar, 2015
Vilanterol - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Vilanterol Indications: Maintenance bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease, in combination with Umeclidinium bromide; Treatment of asthma in combination with Fluticasone furoate; Maintenance treatment of airflow obstruction and for reducing ...

Mar, 2015
Vemurafenib - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Vemurafenib Indications: Treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma Innovator:Roche (Zelboraf) Country ...

Mar, 2015
Umeclidinium bromide, Vilanterol - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Umeclidinium bromide, Vilanterol Indications: Maintenance bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease Innovator:GlaxoSmithKline (Anoro Ellipta, Laventair) Country ...

Mar, 2015
Umeclidinium bromide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Umeclidinium bromide Indications: Maintenance treatment to relieve symptoms of chronic obstructive pulmonary disease Innovator:GlaxoSmithKline (Incruse, Incruse Ellipta) Country ...

Mar, 2015
Tofacitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Tofacitinib Indications: Treatment of psoriasis; Treatment of rheumatoid arthritis optionally in combination with Methotrexate Innovator:Pfizer (Xeljanz) Country ...

Mar, 2015
Telithromycin - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Treatment of mild or moderate community-acquired pneumonia; Treatment of infections caused by known or suspected beta-lactam and/or macrolide resistant strains covered by the antibacterial spectrum of Telithromycin; Treatment of acute exacerbation of chronic bronchitis; Treatment of acute sinusitis; Treatment ...

Mar, 2015
Telaprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Telaprevir Indications: Treatment of chronic hepatitis C genotype 1 infection in combination with Peginterferon alfa and Ribavirin Innovator:Vertex Pharm (Incivek); Janssen (Incivo) Country ...

Mar, 2015
Teduglutide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Teduglutide Indications: Treatment of short bowel syndrome Innovator:NPS Pharma (Revestive, Gattex) Country ...

Mar, 2015
Tedizolid - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Tedizolid Indications: Treatment of acute bacterial skin and skin structure infections Innovator:Cubist Pharm (Sivextro) Country ...

Mar, 2015
Tasimelteon - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Tasimelteon Indications: Treatment of non-24-hour sleep-wake disorder Innovator:Vanda Pharm (Hetlioz) Country ...

Mar, 2015
Tafluprost - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Tafluprost Indications: Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension, optionally as adjunctive therapy to beta blockers Innovator:Santen (Taflotan, Tapros); Merck (Saflutan, Zioptan) Country ...

Mar, 2015
Solithromycin - Comprehensive patent search US$ 7,500.00

... Comprehensive litigation alerts linked to patent numbers Add your own notes, save searches and results This report covers: International Nonproprietary Name: Solithromycin Indications: Treatment of community-acquired bacterial pneumonia; Treatment of gonorrhoea; Treatment of bacterial infections ...

Mar, 2015
Simoctocog Alfa - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Simoctocog Alfa Indications: Treatment and prophylaxis of bleeding in patients with haemophilia A Innovator: Octapharma (Nuwiq) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA Please note that 51 country ...

Mar, 2015
Simoctocog Alfa - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. !NOW WITH ‘USA VIEW’! 'The most extensive source of patent ... Simoctocog Alfa Indications: Treatment and prophylaxis of bleeding in patients with haemophilia A Innovator:Octapharma (Nuwiq) Country ...

Mar, 2015
Ruxolitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Ruxolitinib Indications: Treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF Innovator:Incyte (Jakafi); Novartis (Jakavi) Country ...

Mar, 2015
Rufinamide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Rufinamide Indications: Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome Innovator:Eisai (Banzel, Inovelon) Country ...

Mar, 2015
Roflumilast - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Roflumilast Indications: Treatment and maintenance of severe chronic obstructive pulmonary disease, optionally in combination with bronchodilators and/or corticosteroids Innovator:Nycomed (Daxas, Libertek); Merck (Daxas); Forest Res (Daliresp); Tadeka (Daxas) Country ...

Mar, 2015
Rilpivirine - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Rilpivirine Indications: Treatment of HIV-1 in combination with Ritonavir and other antiretroviral agents Innovator:Tibotec (Edurant); Gilead (Eviplera); Janssen (Edurant) Country ...

Mar, 2015
Retigabine - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Retigabine Indications: Adjunctive treatment of partial onset seizures Innovator:Glaxosmithkline (Trobalt); Valeant (Potiga) Country ...

Mar, 2015
Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Repaglinide Indications: Treatment of type 2 diabetes mellitus Innovator:Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Country ...

Mar, 2015
Ranelic acid - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... and results This report covers: International Nonproprietary Name: Ranelic acid Indications: Treatment of postmenopausal osteoporosis to reduce the risk of fractures, optionally in combination with Vitamin D and/or Calcium Innovator:Servier (Protos, Osseor, Protelos) Country ...

Mar, 2015
Quetiapine - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Quetiapine Indications: Treatment of schizophrenia; Treatment of depressive episodes associated with bipolar disorder; Treatment or prevention of relapse/recurrence of manic, depressive or mixed episodes of bipolar disorder or of acute mania associated with bipolar disorder ...

Mar, 2015
Ponatinib - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Ponatinib Indications: Treatment of chronic phase, accelerated phase or blast phase chronic myeloid leukaemia or Philadelphia chromosome positive acute lymphoblastic leukaemia in patients with T315I mutation or no other tyrosine kinase therapy is indicated Innovator:Ariad Pharm (Iclusig) Country ...

Mar, 2015
Plerixafor - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Plerixafor Indications: Mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma in combination with granulocyte-colony stimulating factor; Treatment to mobilize progenitor cells prior to stem cell ...

Mar, 2015
Plerixafor - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Plerixafor Indications: Mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma in combination with granulocyte-colony stimulating factor; Treatment to mobilize progenitor cells prior to stem cell ...

Mar, 2015
Phenylephrine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Phenylephrine Indications: Maintenance of an adequate level of blood pressure during spinal and inhalation anaesthesia; Prolonging of spinal anaesthesia; Use in regional analgesia as a vasoconstrictor; Treatment of vascular failure in shock, shock-like states, and drug ...

Mar, 2015
Phenylephrine - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Phenylephrine Indications: Maintenance of an adequate level of blood pressure during spinal and inhalation anaesthesia; Prolonging of spinal anaesthesia; Use in regional analgesia as a vasoconstrictor; Treatment of vascular failure in shock, shock-like states, and drug ...

Mar, 2015
Ospemifene - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Ospemifene Indications: Treatment of moderate to severe dyspareunia Innovator:Shionogi (Osphena) Country ... patent documents and national registers is provided at no additional charge. About GenericsWeb: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from Ark Patent ...

Mar, 2015
Ospemifene - Comprehensive patent search US$ 6,200.00

... searches and results This report covers: International Nonproprietary Name: Ospemifene Indications: Treatment of moderate to severe dyspareunia Innovator:Shionogi (Osphena) Country coverage: The In-depth search contains patents ...

Mar, 2015
Oseltamivir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... patent documents and national registers is provided at no additional charge. About GenericsWeb: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from Ark Patent ...

Mar, 2015
Oseltamivir - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Name: Oseltamivir Indications: Treatment and prophylaxis of Influenza Innovator:Roche (Tamiflu) Country ... patent documents and national registers is provided at no additional charge. About GenericsWeb: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from Ark Patent ...

Mar, 2015
Omarigliptin - Comprehensive patent search US$ 6,200.00

... Comprehensive litigation alerts linked to patent numbers Add your own notes, save searches and results This report covers: International Nonproprietary Name: Omarigliptin Indications: Treatment of type 2 diabetes mellitus ...

Mar, 2015
Ocriplasmin - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) US$ 1,400.00

... Ocriplasmin Indications: Treatment of symptomatic vitreomacular adhesion Innovator:ThromboGenics (Ocriplasmin); Alcon (Ocriplasmin) Country ...

Mar, 2015
Nevirapine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Nevirapine Indications: Treatment of HIV-1 infection in combination with other antiretroviral agents, such as Lamivudine, Stavudine, Zidovudine and Tenofovir Innovator: Boehringer Ingelheim (Viramune, Viramune XR) Country ...

Mar, 2015
1 2 3 4 5 >
Skip to top